arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Iovance Biotherapeutics, Inc.

IOVA Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$14.14
▼ -4.8% Today
as of Oct 22, 16:49 ET
Last 30 days +52.70% Sep 14 → Oct 22
$8.81 $10.44 $12.06 $13.68 $15.31 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$14.32
High
$14.70
Low
$13.67
Volume
$11M
Avg Vol
$16M
Mkt Cap
$5.9B
P/E (TTM)
—
Beta
—
52w High
$15.37
52w Low
$1.76
Div Yield
—
Shares Out
$453M

Recent Press Releases & News last 60 days · 25 items

Oct 19 · 11:00 PR GlobeNewswire
Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026
Oct 16 · 21:15 PR GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Oct 4 · 04:56 Insider Monkey
Why Iovance Biotherapeutics (IOVA) Effortlessly Soared 256% in Q3
▸ Show all 25 press releases & news Free account →

IOVA earnings at a glance

Iovance Biotherapeutics, Inc. (IOVA) is scheduled to report earnings on Thursday, November 5, 2026 — in 13 days. Analysts expect earnings per share of -$0.09, compared with -$0.25 in the same quarter last year (+64%). The options market is pricing a move of about ±5.6% after the report, a range of roughly $13.35 to $14.93 from today's $14.14. Over its last 6 reports the stock rose the next day 3 times and fell 3, moving ±29.9% on average; after the most recent report on Aug 6, 2026 it moved +43.1%. That means options currently expect less movement than IOVA has typically delivered. IOVA beat the consensus EPS estimate in 3 of its last 6 reported quarters. Implied volatility is currently 134%. The share price of $14.14 sits near its 52-week high.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$1.76
$15
91% of range
Avg surprise (last 6)
+1.6%
Avg reaction (last 6)
+3.9%
50% positive
Latest IV / EM
134%
EM ±5.6% · $14 · Oct 9

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.50$-0.40$-0.30$-0.21$-0.11 Actual $-0.50Actual $-0.47Actual $-0.46Actual $-0.42Actual $-0.34Actual $-0.28Actual $-0.36Est $-0.25Actual $-0.33Est $-0.29Actual $-0.25Est $-0.29Actual $-0.18Est $-0.22Actual $-0.19Est $-0.19Actual $-0.11Est $-0.17 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-116M$-61M$-6M$49M$104M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Thu Aug 6, 2026Jun/2026 $-0.11 $-0.17 +35.3% +48.5% +43.1% earnings
Thu May 7, 2026Mar/2026 $-0.19 $-0.19 0.0% +47.2% -13.2% earnings
Tue Feb 24, 20268K 2026-02-24 $-0.18 $-0.22 +18.2% — +30.8% earnings
Thu Nov 6, 2025Sep/2025 $-0.25 $-0.29 +13.8% — +27.6% earnings
Thu Aug 7, 2025Jun/2025 $-0.33 $-0.29 -13.8% — -20.1% earnings
Thu May 8, 2025Mar/2025 $-0.36 $-0.25 -44.0% — -44.8% earnings
Mon Sep 30, 2024Sep 2024 $-0.28 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.34 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.42 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.46 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.47 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.50 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Thu Nov 5, 2026Sep/2026OTHER -$0.09-$0.25 +64.0%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$99M$71M—$67M$60M$49M—$59M
Cost of revenue$44M$42M—$38M$49M$43M—$32M
Gross profit————————
Operating income$-52M$-81M—$-95M$-114M$-121M—$-89M
Net income$-47M$-79M—$-91M$-112M$-116M—$-84M
EPS (diluted)$-0.11$-0.19——$-0.33$-0.36—$-0.28

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$111M$197M$163M$158M$132M$172M$116M$164M
Inventory$56M$58M$52M$52M$50M$66M$52M$39M
Total current assets$464M$467M$443M$429M$422M$513M$457M$499M
Total assets$916M$926M$913M$905M$907M$967M$910M$991M
Long-term debt————————
Total liabilities$179M$204M$215M$203M$209M$199M$200M$218M
Total equity$736M$722M$699M$702M$698M$768M$710M$773M

Implied volatility — last 90 days

42%271%501%731%961% Jun 07 — IV 76% · EM ±7.1%Jun 08 — IV 105% · EM ±8.8%Jun 09 — IV 176% · EM ±12.7%Jun 10 — IV 178% · EM ±10.5%Jun 11 — IV 121% · EM ±5.1%Jun 15 — IV 103% · EM ±7.5%Jun 16 — IV 144% · EM ±8.5%Jun 17 — IV 121% · EM ±5.1%Jun 19 — IV 81% · EM ±9.0%Jun 22 — IV 88% · EM ±7.3%Jun 23 — IV 170% · EM ±12.3%Jun 25 — IV 370% · EM ±15.4%Jun 29 — IV 60% · EM ±14.2%Jun 30 — IV 47% · EM ±10.8%Jul 03 — IV 42% · EM ±4.6%Jul 06 — IV 107% · EM ±8.9%Jul 07 — IV 102% · EM ±7.4%Jul 08 — IV 961% · EM ±56.8%Jul 09 — IV 299% · EM ±12.5%Jul 13 — IV 88% · EM ±7.4%Jul 14 — IV 79% · EM ±5.7%Jul 15 — IV 153% · EM ±9.0%Jul 16 — IV 307% · EM ±12.8%Jul 20 — IV 89% · EM ±7.4%Jul 21 — IV 120% · EM ±8.7%Jul 22 — IV 131% · EM ±7.7%Jul 23 — IV 187% · EM ±7.8%Jul 27 — IV 98% · EM ±8.2%Jul 29 — IV 185% · EM ±10.9%Jul 30 — IV 229% · EM ±9.5%Aug 03 — IV 242% · EM ±20.3%Aug 04 — IV 277% · EM ±20.1%Aug 05 — IV 648% · EM ±38.3%Aug 06 — IV 175% · EM ±7.3%Aug 10 — IV 75% · EM ±6.2%Aug 11 — IV 75% · EM ±5.4%Aug 12 — IV 164% · EM ±9.7%Aug 13 — IV 110% · EM ±4.6%Aug 17 — IV 105% · EM ±8.8%Aug 18 — IV 118% · EM ±8.6%Aug 19 — IV 117% · EM ±6.9%Aug 20 — IV 186% · EM ±7.8%Aug 24 — IV 111% · EM ±9.3%Aug 25 — IV 102% · EM ±7.4%Aug 26 — IV 105% · EM ±6.2%Aug 27 — IV 204% · EM ±8.5%Aug 31 — IV 102% · EM ±8.5%Sep 01 — IV 113% · EM ±8.2%Sep 02 — IV 98% · EM ±5.8%Sep 03 — IV 179% · EM ±7.5%Sep 07 — IV 112% · EM ±9.4%Sep 08 — IV 87% · EM ±6.3%Sep 09 — IV 90% · EM ±5.3%Sep 14 — IV 110% · EM ±9.2%Sep 15 — IV 107% · EM ±7.7%Sep 16 — IV 77% · EM ±4.5%Sep 17 — IV 84% · EM ±3.5%Sep 21 — IV 79% · EM ±6.6%Sep 22 — IV 137% · EM ±9.9%Sep 23 — IV 112% · EM ±6.6%Sep 24 — IV 128% · EM ±5.3%Sep 28 — IV 86% · EM ±20.4%Sep 29 — IV 113% · EM ±26.2%Sep 30 — IV 117% · EM ±6.9%Oct 01 — IV 92% · EM ±3.8%Oct 05 — IV 84% · EM ±7.0%Oct 06 — IV 88% · EM ±6.4%Oct 07 — IV 88% · EM ±5.2%Oct 08 — IV 134% · EM ±5.6%

Sector peers

CGON
CG Oncology, Inc.
$6.1B $62.54+1.0%
SRRK
Scholar Rock Holding Corporation
$5.6B $41.96+1.4%
KOD
Kodiak Sciences Inc
$6.2B $85.78-7.7%
CRSP
CRISPR Therapeutics AG
$5.4B $49.99+0.2%
IMVT
Immunovant, Inc.
$7.0B $29.10+1.8%
ADPT
Adaptive Biotechnologies Corporation
$4.2B $24.41-0.0%

IOVA earnings FAQ

When is IOVA's next earnings date?

Iovance Biotherapeutics, Inc. is expected to report on November 5, 2026.

What is IOVA's expected move for earnings?

Options currently price a move of about ±5.6%, or $0.79 per share either way from $14.14.

How does IOVA stock usually react to earnings?

Across the last 6 reports the average next-day move was ±29.9%, up 3 times and down 3 times.

What EPS are analysts expecting from Iovance Biotherapeutics, Inc.?

The consensus estimate is -$0.09 per share, versus -$0.25 a year ago.

What is IOVA's implied volatility?

IOVA's at-the-money implied volatility is about 134% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in